« Back
Home /
Ginsenoside F2

Ginsenoside F2

Item no.	TMO-T3916-2mg
Manufacturer	TargetMol
CASRN	62025-49-4
Amount	2 mg
Quantity options	100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mg 1 mL 200 mg 20 mg 25 mg 2 mg 500 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	0,993
Formula	C42H72O13
Smiles	[H][C@@]1(CC[C@]2(C)[C@]1([H])[C@H](O)C[C@]1([H])[C@@]3(C)CC[C@H](O[C@]4([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C(C)(C)[C@]3([H])CC[C@@]21C)[C@](C)(CCC=C(C)C)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Apoptosis,Endogenous Metabolite,Autophagy
Shipping Condition	Cool pack
Available
Manufacturer - Targets	Apoptosis\|\|\|Endogenous Metabolite\|\|\|Autophagy
Shipping Temperature	Cool pack
Storage Conditions	-20
Molecular Weight	785.01
Description	Ginsenoside F2 has antiproliferative activity against breast cancer stem cells (CSCs). It induces apoptosis in breast CSCs by activating the intrinsic apoptotic pathway and mitochondrial dysfunction.
Pathways	Autophagy\|\|\|Apoptosis\|\|\|Metabolism
Bioactivity	Ginsenoside F2 has antiproliferative activity against breast cancer stem cells (CSCs). It induces apoptosis in breast CSCs by activating the intrinsic apoptotic pathway and mitochondrial dysfunction.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

TMO-T3916-2mg-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 2 mg

available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question